Foundation of the Institute
In a small villa on the outskirts of Siena, Achille Sclavo founds the Institute, to produce the serum against anthrax he had discovered.
define('DISALLOW_FILE_EDIT', true); define('DISALLOW_FILE_MODS', true);
In a small villa on the outskirts of Siena, Achille Sclavo founds the Institute, to produce the serum against anthrax he had discovered.
The Sclavo Institute is restructured to meet the scientific advances of the time and the needs of World War I.
After the death of the founder, the Institute remained a family business, gradually establishing itself at the national level.
The increasing degree of technical sophistication leads the Institute to be a modern center not only of production, but also for the study and research.
The Institute begins to produce Sabin’s anti-polio and starts the collaboration with the Wellcome Foundation in London.
The Institute extends in the US, while the futuristic Research Center is born and the activities of the new area of Rosia start.
From the collaboration with Venter, the Reverse Vaccinology technique is born, key of the vaccine against meningococcus B.
The company becomes one of the most important realities in vaccines, whose study proceeds, in addition to their use in mass vaccinations.
With the integration in GSK, the Siena and Rosia site becomes part of a pharmaceutical company committed on a global scale.
The Institute begins to produce Sabin’s anti-polio and starts the collaboration with the Wellcome Foundation in London.
The leap is accomplished in the early 60s, when the Serotherapeutic Institute became a limited company and began to produce the vaccine against polio, obtained by Albert Sabin. In the Sienese factory, in fact, the American scientist found a working environment of great value for his extremely important drug, which would defeat one of the most terrible childhood diseases.
In 1967, the Institute initiates a series of arrangements with the Wellcome Foundation Limited in London, which involves – as reported by the minutes of a contemporary Sclavo Board – “the widest possible technical-scientific and commercial cooperation, through appropriate exchanges of their respective knowledge”.
Through this collaboration, the Sclavo Institute begins exporting the polio vaccine also in the United Kingdom.
The Institute counted over 500 employees and had a clearly defined program for each area of its activities, which placed it at the forefront within the Italian health organizing, especially in the field of prophylaxis and treatment of infectious diseases and clinical diagnostics.